Kaomi ma aneʻi e hōʻike i kāu mau hae ma kēia ʻaoʻao a uku wale no ka holomua

Nuhou Uea

Haʻawina Pivotal Phase 3 Oral Insulin Study

i kakauia ma hoʻoponopono

Ua hoʻolaha ʻo Oramed Pharmaceuticals Inc. i kēia lā ua hoʻopau ʻo ia i ka hoʻopaʻa inoa ʻana o nā mea maʻi no kāna Phase 3 ORA-D-013-1 haʻawina o kāna capsule insulin waha ORMD-0801 no ka mālama ʻana i ka maʻi maʻi type 2 (T2D), ʻoi aku i kāna pahuhopu o 675 mau maʻi me 710 nā maʻi i kākau inoa.             

ʻO ORA-D-013-1 ka nui o nā haʻawina ʻelua Phase 3 o Oramed e mālama ʻia ana ma lalo o nā protocols i ʻae ʻia e ka US Food and Drug Administration (FDA) e mālama i nā maʻi T2D i lawa ʻole ka mana glycemic ma kahi manawa o 6 a 12 mau mahina. Loaʻa ka ʻikepili kūpono no ORA-D-013-1 ma hope o ka pau ʻana o nā maʻi āpau i ka manawa mālama 6 mahina mua.

"ʻOliʻoli mākou i ka hoʻolaha ʻana i ka haʻawina insulin waha mua o ka Phase 3 o ka honua, i mālama ʻia ma lalo o kahi protocol FDA, ua loaʻa i kahi mea nui me ka pau ʻana o ke kau inoa. Ma hope o ʻeono mahina o ka mālama ʻana o ka mea maʻi, manaʻo mākou e hoʻolaha i nā hopena topline ma Ianuali 2023, "wahi a Oramed CEO Nadav Kidron. "ʻOliʻoli loa mākou i ka manaʻo o kahi koho insulin waha no ka poʻe e noho ana me ka maʻi diabetes. Hāʻawi ʻia ma ka waha, hoʻohālikelike ka insulin waha i ka hoʻoponopono o ka insulin endogenous ma mua o ka hiki ʻana i ke kahe koko, e hāʻawi ana i ka ʻoi aku ka maikaʻi o ka hoʻokele glucose koko a hiki ke hōʻemi i nā pilikia a me nā pilikia e pili ana i ka insulin injectable, me ka loaʻa ʻana o ke kaumaha a me ka hypoglycemia, ʻoiai ʻoi aku ka maʻalahi o ka lawelawe ʻana. Makemake au e hoʻomaikaʻi aku i nā poʻe maʻi āpau, nā mea noiʻi a me nā hoa pili i kēia hoʻokolohua lapaʻau, nā mea āpau me ka pahuhopu maʻamau o ka lawe ʻana i kahi holomua o ka maʻi diabetes.

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo

Kaʻana like i...